Design, synthesis and biological activity of oxyevodiamine-based histone deacetylase 6 inhibitors.

J Asian Nat Prod Res

Beijing Key Laboratory of Active Substance Discovery and Drug ability Evaluation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.

Published: November 2024

Histone deacetylase 6 (HDAC6) was a potential target for Alzheimer's disease (AD). In this study, a series of novel oxyevodiamine-based HDAC6 inhibitors with a variety of linker moieties were designed, synthesized and evaluated. Compound with a benzyl linker was identified as a high potent and selective HDAC6 inhibitor. It inhibited HDAC6 with an IC value of 6.2 nM and was more than 200 fold selectivity over HDAC1. It also had lower cytotoxicity and higher anti-HO activity comparing with other derivatives. Compound might be a good lead as novel HDAC6 inhibitor for the treatment of AD.

Download full-text PDF

Source
http://dx.doi.org/10.1080/10286020.2024.2362383DOI Listing

Publication Analysis

Top Keywords

histone deacetylase
8
hdac6 inhibitor
8
hdac6
5
design synthesis
4
synthesis biological
4
biological activity
4
activity oxyevodiamine-based
4
oxyevodiamine-based histone
4
deacetylase inhibitors
4
inhibitors histone
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!